Study title: BL 103836,GCGD4-002 - Long-term safety and efficacy of Actimmune therapy in children with chronic granulomatous disease (CGD): Summary of data from the National Institutes of Health cohort in children initiating Actimmune prior to 1 year of age and prior to 3 years of age, respectively.
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Immune System Diseases [C20] | |||||
Brands: Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: INTERFERON GAMMA (1B) | |||||
ATC code: | |||||
Document link: | |||||
Document date: | |||||
Study number: GCGD4-002 | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | Y | Y | - |